Actively Recruiting
Randomized Phase II Study Evaluating Different Doses of GHZ339 Compared to Placebo in Adults with Moderate to Severe Atopic Dermatitis
Led by Novartis Pharmaceuticals · Updated on 2026-09-28
224
Participants Needed
105
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating several investigational compounds for people with moderate to severe atopic dermatitis AD. This multicenter, randomized, double-blind, placebo-controlled Phase II platform study aims to assess the safety and effectiveness of these treatments, with Novartis Pharmaceuticals sponsoring the trial. The study focuses on improving skin symptoms and disease severity in participants diagnosed with AD for at least one year. The first treatment being tested is GHZ339, which will be given in different doses labeled A, B, C, and D. Participants are randomly assigned to study groups where they will receive a specific dose of GHZ339 or a placebo during the first treatment period. In the second treatment period, they continue with the same or adjusted dose, depending on their initial assignment. Placebo recipients in the first period will receive one of the GHZ339 doses during the second period. During the study, participants will have assessments including the Eczema Area and Severity Index EASI to measure disease changes, along with Investigator Global Assessment IGA scores at baseline and at 16 weeks. Researchers will monitor safety through laboratory tests and clinical evaluations. The total duration participants are followed corresponds to the treatment and assessment periods, and the main focus is tracking improvements in skin condition and overall disease status.
CONDITIONS
Brief Title
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here